Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.560 +0.310 (+4.96%)
Streaming Delayed Price Updated: 3:05 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke ↗
The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of... 
Via Benzinga
News headline image
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
38 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize... 
Via Benzinga
News headline image
51 Biggest Movers From Friday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 32.67% to $67.0 during Friday's pre-market session. The company's market cap stands at $860.7... 
Via Benzinga
News headline image
30 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Celcuity Inc. (NASDAQ: CELC) rose 32.3% to $19.00 in pre-market trading after the company reported a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
News headline image
10 Stocks Moving In Thursday's After-Hours Session ↗
Gainers FuboTV (NYSE: FUBO) shares are trading higher after the company announced it acquired exclusive streaming rights to the Qatar World Cup 2022 Qualifying matches of South... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers DiaMedica Therapeutics (NASDAQ:DMAC) shares increased by 6.17% to $9.98 during Thursday's after-market session. DiaMedica Therapeutics's trading volume hit 12.0K... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.